Why the study?
Do ENDURALIFE-powered CRT-D devices improve battery longevity and reduce costs compared to other CRT-D devices in patients with heart failure?
Do ENDURALIFE-powered CRT-D devices improve battery longevity and reduce costs compared to other CRT-D devices in patients with heart failure?
ENDURALIFE-powered CRT-D devices received a positive NICE recommendation due to increased battery longevity and projected cost savings of £2120-£5627 per patient over 15 years.
No takes yet. Share an insight, caveat, or question.
Supports NICE adoption of ENDURALIFE CRT-Ds for HF; leaves open need for comparative long-term data.
Evans et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: